Psoriatic arthritis (PsA) is a chronic inflammatory disease that can reduce mobility and agility in patients. PsA is known to increase the risk of type II diabetes. A recent study published in The FASEB Journal tested a novel mouse model that may one day lead to therapeutic approaches or reagents for human skin pathology, as well as joint erosion and disc degeneration, that would improve quality of life for patients with PsA.
* This article was originally published here
